Glucose control mediated by exenatide once-weekly (EQW). (a) Change from baseline in hemoglobin A1c (HbA1c) in the placebo-controlled trial (Kim et al.27) and DURATION-1, -2, and -3.28,30,31 (b) Change from baseline in fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) in DURATION-1.28 EBID, exenatide twice-daily; Glar, insulin glargine; Pio, pioglitazone; Sita, sitagliptin. *P<0.05 versus comparators.